AbbVie Acquires Privately Held Aliada Therapeutics for $1.4 Billion, Boosting Alzheimer's Focus with ALIA-1758

Oct 28, 2024, 12:11 PM

AbbVie Inc. has announced the acquisition of privately held Aliada Therapeutics for $1.4 billion in cash. This strategic move aims to bolster AbbVie's focus on Alzheimer's disease and its neuroscience pipeline. The acquisition includes Aliada's lead compound, ALIA-1758, and novel blood-brain barrier technology. The deal represents a significant return on investment for venture capital, with an initial investment of $33 million yielding $1.4 billion.